Skip to main content
. 2025 Jul 25;15(16):8488–8508. doi: 10.7150/thno.114534

Figure 4.

Figure 4

In vivo biodistribution of GB4-BPL. (A) The representative small animal living images of each group of the BmCRPC-bearing mice at 0-24 h, post-injection (yellow circle: tumor area). Lipo8000@DiR, GB4-lipo@DiR and GB4-BPL@DiR were injected at a DiR concentration of 1 mg/kg. (B) The qualified distribution in tumors, bones and major organs of each group. (C) Fluorescence imaging of tumors, bones and major organs. (D) Total luminescence quantification of the dissected left leg, and right leg for Lipo8000, GB4-lipo and GB4-BPL -treated mice. (E) Left legs, and right legs were dissected for luminescence imaging. (F) Image analysis of intratumor permeation of DiR-labeled Lipo8000, GB4-lipo, and GB4-BPL. (G) Intertumoral permeation in whole tumor mass by CLSM detections, scale bars = 500 μm. (H) Statistical analysis of mean fluorescence intensity for frozen tumor sections in each group. Data are mean ± SD (n = 3), *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA.